Baricitinib 2 mg/day as a Cost-conscious Entry Point to Systemic Therapy in Moderate-to-severe Atopic Dermatitis: Real-world Data from a Japanese Clinic
DOI:
https://doi.org/10.2340/actadv.v105.43616Keywords:
Atopic Dermatitis, Baricitinib, JAK inhibitor, pruritus, real world data, low doseDownloads
References
Simpson EL, Bieber T, Eckert L, Wu R, Ardeleanu M, Graham NMH, et al. Patient burden of moderate to severe atopic dermatitis (AD): insights from a phase 2b clinical trial of dupilumab in adults. J Am Acad Dermatol 2016; 74: 491–498. DOI: https://doi.org/10.1016/j.jaad.2015.10.043
Simpson E, Armstrong A, Boguniewicz M, Fuxench ZCC, Feely M, Pierce E, et al. Baricitinib 2 mg for the treatment of atopic dermatitis in North America: long-term efficacy and patient-reported outcomes. Dermatol Ther 2022; 35: e15954. DOI: https://doi.org/10.1111/dth.15954
Silverberg JI, Boguniewicz M, Waibel J, Weisman J, Strowd L, Sun L, et al. Clinical tailoring of baricitinib 2 mg in atopic dermatitis: baseline body surface area and rapid onset of action identifies response at week 16. Dermatol Ther 2022; 12: 137–148. DOI: https://doi.org/10.1007/s13555-021-00640-7
Pourali SP, Nscuti L, Dusetzina SB. Out-of-pocket costs of specialty medications for psoriasis and psoriatic arthritis treatment in the Medicare population. JAMA Dermatol 2021; 157: 1239–1241. DOI: https://doi.org/10.1001/jamadermatol.2021.3616
Schaefer CP, Cappelleri JC, Cheng R, Cole JC, Guenthner S, Fowler J, et al. Health care resource use, productivity, and costs among patients with moderate to severe plaque psoriasis in the United States. J Am Acad Dermatol 2015; 73: 585–593. DOI: https://doi.org/10.1016/j.jaad.2015.06.049
Feldman SR, Cox LS, Strowd LC, Gerber RA, Faulkner S, Sierka D, et al. The challenge of managing atopic dermatitis in the United States. Am Health Drug Benefits 2019; 12: 83–93.
Heinz KC, Beaudart C, Willems D, Wiethoff I, Hiligsmann M. Cost-effectiveness of emerging treatments for atopic dermatitis: a systematic review. PharmacoEcon 2023; 41: 1415–1435. DOI: https://doi.org/10.1007/s40273-023-01293-4
Liu B, Song X, Liao S, Luan T, Zhao Z. Comparison of efficacy of baricitinib and dupilumab in the treatment of Chinese moderate-to severe atopic dermatitis: a retrospective study. Int Arch Allergy Immunol 2023; 184: 966–974. DOI: https://doi.org/10.1159/000530394
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Masato Mizuashi
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
